Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Brenipatide in Moderate-to-Severe Alcohol Use Disorder (RENEW-ALC-1)
NCT07219966Phase 3Recruiting
- Sponsor
- Eli Lilly and Company
- Start
- Oct 2025
- Primary completion
- Apr 2028
- Modality
- Peptides
- Countries
- 8
01
Overview
A Phase 3 trial of brenipatide in alcohol use disorder (AUD), sponsored by Eli Lilly and Company. Started Oct 2025; status: recruiting.
02
Drugs
brenipatide
03
Conditions
alcohol use disorder (AUD)
Beyond the preview
Go deeper on NCT07219966.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT07219966.